Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer.
Kito Y, Machida N, Kawai S, Hamauchi S, Tsushima T, Todaka A, Yokota T, Yamazaki K, Fukutomi A, Onozawa Y, Tsuji K, Doyama H, Haraguchi Y, Nakashima K, Kunieda K, Taku K, Mori K, Yasui H. Kito Y, et al. Among authors: mori k. Int J Clin Oncol. 2018 Dec;23(6):1084-1089. doi: 10.1007/s10147-018-1308-1. Epub 2018 Jun 21. Int J Clin Oncol. 2018. PMID: 29931597 Clinical Trial.
Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens.
Tokito T, Kenmotsu H, Watanabe R, Ito I, Shukuya T, Ono A, Nakamura Y, Tsuya A, Naito T, Murakami H, Takahashi T, Ohde Y, Kondo H, Endo M, Kameya T, Nakajima T, Mori K, Yamamoto N. Tokito T, et al. Among authors: mori k. Int J Clin Oncol. 2014 Feb;19(1):63-7. doi: 10.1007/s10147-012-0509-2. Epub 2012 Dec 19. Int J Clin Oncol. 2014. PMID: 23250620
Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine.
Imai H, Shukuya T, Yoshino R, Muraki K, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Tomizawa Y, Takahashi T, Takahashi K, Saito R, Yamamoto N. Imai H, et al. Among authors: mori k. Chemotherapy. 2013;59(4):307-13. doi: 10.1159/000356155. Epub 2014 Jan 24. Chemotherapy. 2013. PMID: 24480845
Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.
Imai H, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, Takahashi T. Imai H, et al. Among authors: mori k. Med Oncol. 2014 Aug;31(8):88. doi: 10.1007/s12032-014-0088-3. Epub 2014 Jun 25. Med Oncol. 2014. PMID: 24961467 Clinical Trial.
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Ko R, Kenmotsu H, Hisamatsu Y, Akamatsu H, Omori S, Nakashima K, Oyakawa T, Wakuda K, Shukuya T, Ono A, Imai H, Taira T, Naito T, Murakami H, Mori K, Endo M, Ohde Y, Takahashi K, Takahashi T. Ko R, et al. Among authors: mori k. Int J Clin Oncol. 2015 Aug;20(4):668-73. doi: 10.1007/s10147-014-0761-8. Epub 2014 Oct 25. Int J Clin Oncol. 2015. PMID: 25343946
7,608 results